Watch the “What This Means" segment here HOUSTON, June 18, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ( ...

The results suggest toxicity may not be as pervasive as previously thought, which argues for more-personalized monitoring.

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin” or the "Company”), a late-stage pharmaceutical company with a broad ...

FDA recommends inclusion of patients as young as 6 months - younger than Moleculin had proposed - to be allowed in the ...

Annamycin aims to eliminate cardiotoxicity associated with anthracyclines used to treat about 60% of all children with cancer FDA recommends inclusion of patients as young as 6 months - younger than ...

A new study from Washington University School of Medicine in St. Louis identifies a possible way to slow or block progression ...

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...

Scientists created a new weight-loss drug that protects blood sugar levels and muscle mass. The new weight-loss tablet was ...

An article published in the journal Nature Metabolism presents an experimental drug that stimulates adipose tissue cells to ...

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...